Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 1 of 212

Drugmakers’ hopes for gene therapy rise despite tiny sales in Europe

The science of gene therapy is finally delivering on its potential, and drugmakers are now hoping to produce commercially viable medicines after tiny sales for the first two such treatments in Europe.

Read More »

EU tests limits of drug pricing freedom in landmark probe

The first ever EU antitrust probe into excessive drug pricing is taking the European pharmaceuticals industry into uncharted territory, unnerving some companies and lawyers worried about the reach of market intervention.

Read More »

Google backs new European biotech drug fund

Google is betting on the potential of European biotech companies to deliver life-changing drugs by investing alongside Swiss company Novartis in a new $300 million fund run by leading life sciences investment firm Medicxi.

Read More »

European Commission Approves Pfizer’s Trumenba to Help Prevent Meningococcal Group B Disease in Adolescents and Adults

Pfizer Inc. announced that the European Commission approved Trumenba (Meningococcal Group B Vaccine) for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) in individuals 10 years of age and older.

Read More »

UK biotech boasts Europe’s best pipeline as Brexit threat looms

Britain’s biotech sector boasts the strongest new drug pipeline in Europe but industry leaders say it needs continued access to global talent, funding and regulatory clarity to thrive in the future – all of which could be jeopardized by Brexit.

Read More »

In Europe, U.S., modern AIDS drugs add extra 10 years of life expectancy

Life expectancy for young HIV-positive adults has risen by 10 years in the United States and Europe.

Read More »

Gilead hepatitis C drug patent faces European challenge

International groups representing doctors and patients have launched a fresh challenge to the patent on Gilead Sciences’ hepatitis C drug sofosbuvir at the European Patent Office in order to increase access to the treatment.

Read More »

Diabetes study: Many common genes at play

A study examining genes of more than 120,000 people from Europe, Asia, Africa and the Americas has offered the clearest picture yet of those that drive type 2 diabetes.

Read More »

Sanofi says LixiLan diabetes drug trials meet targets

France’s Sanofi said two late-stage Phase III clinical trials of its LixiLan diabetes drug had met their targets, readying it for approval in the United States in August and Europe in early 2017.

Read More »

Zika virus may spread to Europe in coming months, WHO warns

The Zika virus may spread into Europe as the weather gets warmer, although the risk is low, health officials said.

Read More »

UBS, MPM team up on $471 million cancer fund to speed drug development

A $471 million UBS venture fund aims to generate annual returns “north of 10 percent” for its European and Asian investors by financing new cancer drugs.

Read More »

Europe is malaria free, 214 million cases in rest of world in 2015: WHO

(Thomson Reuters Foundation) – Europe has become the world’s first region to wipe out malaria, with zero cases reported last year, the World Health Organization (WHO) said on Wednesday. The number of indigenous malaria cases dropped to zero in 2015 from 90,712 in 1995, and the last cases were reported in Tajikistan in 2014, it […]

Read More »

EU extends safety review of chronic Hep C treatments

The EMA said it extended a safety review of chronic hepatitis C treatments after new data showed patients taking the drugs were at risk of their liver cancer returning.

Read More »

2015 U.S. trends in aggregate spend, disclosure, and transparency

What are key trends in the transparency compliance landscape? And, how are life sciences manufacturers tackling growing requirements

Read More »

2016 Annual Report: Top 10 Pipelines

The pharma industry’s R&D concentration has been shifting towards specialty therapy areas as research and development returns decline for some leaders.

Read More »

Biosimilar drugs get boost as UK cost agency backs their use

Cheaper “biosimilar” copies of expensive biotech drugs received a boost in Britain on Tuesday when the country’s health cost-effectiveness agency NICE said patients needing such medicines “should be started with the least expensive drug”. So-called biosimilars are gaining ground in Europe, which has been faster to adopt their use than the United States, offering savings […]

Read More »

Exclusive: Lazard works with Sanofi on $12.7 billion animal health unit deal – sources

Investment bank Lazard is working with Sanofi’s management to prepare a sale or listing of its Merial animal health unit, aiming to land the leading advisory job for the deal, which could value the business at up 12 billion euros ($12.7 billion), sources familiar with the matter said. Lazard is expected to win the role […]

Read More »

Novartis heart failure medicine Entresto wins EU approval

The European Commission has approved Novartis’ Entresto drug for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction, the Swiss drugmaker said on Tuesday.   Entresto is the first new drug in decades for helping patients whose lives are in danger because their hearts cannot pump blood efficiently. Analysts estimate […]

Read More »

EU endorses copy of Enbrel arthritis drug from Samsung, Biogen

A copy of the blockbuster biotech drug Enbrel was recommended for approval in Europe on Friday, making it the second so-called biosimilar antibody medicine to win such a green light from the continent’s regulators. The European Medicines Agency (EMA) said its experts backed the use of South Korean company Samsung Bioepis’s version of etanercept, as […]

Read More »

Array BioPharma And Pierre Fabre Announce Development And Commercialization Collaboration For Two Novel Oncology Products, Binimetinib And Encorafenib

– Array to receive a $30 million up-front payment and up to $425 million in additional development and commercialization milestones, as well as robust double-digit royalties on future sales – – Array retains full commercialization rights to binimetinib and encorafenib in United States, Canada, Japan and Korea – -NEMO Phase 3 trial remains on-track for […]

Read More »

Page 1 of 212

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2017 Focus: Manufacturer of the Year, Top 50 Pharma, HBA and more!

Subscribe

Ad Right Bottom

Main Navigation